Pfizer Inc.

← The SEC Ephemeris: the whole map

Pfizer Inc. Trazimera

In the graph: all 7 documents (362 pages).

Application: BLA 761081
Ticker: PFE
Product: Trazimera
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: April 20, 2018

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

Mylan Pharmaceuticals Inc., a Viatris Company the following drug product: > Abacavir
Nanocopoeia, LLC this action
NeuroDerm, Ltd. carbidopa levodopa
Nevakar, Inc. Norepinephrine Bitartrate
nnoPharma Licensing LLC Acetaminophen njection
Nobelpharma Co., Ltd. sirolimus
NorthStar Medical Radioisotopes, LLC TechneGen Generator
Novartis Pharmaceuticals Corporation inclisiran
Novitium Pharma LLC Hydroxychloroquine Sulfate
Novo Nordisk NNC0148-0287
Ocular Therapeutix, Inc. DEXTENZA
Ocuvex Therapeutics, Inc. brimonidine tartrate
Omeros Corporation OMS721
Orexo AB Naloxone hydrochloride
Organon, Inc. Gepirone hydrochloride
Orphan Therapeutics, LLC Lucassin
Orphazyme A/S arimoclomol
Otsuka Pharmaceutical Company, Ltd. ABILIFY MAINTENA
OWP Pharmaceuticals, Inc. this action
Par Sterile Products, LLC Micafungin
Pfizer Inc. Trazimera
Pfizer Ireland Pharmaceuticals MOD-4023
AB Pharmaceuticals, LLC the following drug product: > Efavirenz
PharmaEssentia Corporation P1101
Pharmaxis Ltd. Bronchitol
Phathom Pharmaceuticals, Inc. Voquezna
Pierre Fabre Pharmaceuticals Inc. tabelecleucel®
Polarean Inc. Xenoview
Provention Bio, Inc. PRV-031
Proximagen, LLC Nayzilam
PTC Therapeutics, Inc. vatiquinone
RB Health (US) LLC naproxen sodium |)
Recordati Rare Diseases Inc. Cystadrops
Recro Pharma Inc. Meloxicam
RedHill Biopharma Ltd. Rizaport
Regeneron Pharmaceuticals, Inc. BLA
REGENXBIO, Inc. clemidsogene lanparvovee
Replimune, Inc. vusolimogene oderparepvec
ResQ Pharma
Revance Therapeutics, Inc. daxibotulinumtoxinA

All 283 on the full map →

Group by

Build queue · replay at pipeline speed